Thrivent Financial For Lutherans Sells 160,520 Shares of Edwards Lifesciences Corporation (EW)
Thrivent Financial For Lutherans reduced its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 22.8% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 543,370 shares of the medical research company’s stock after selling 160,520 shares during the quarter. Thrivent Financial For Lutherans owned approximately 0.26% of Edwards Lifesciences Corporation worth $64,248,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also made changes to their positions in the company. NEXT Financial Group Inc increased its position in Edwards Lifesciences Corporation by 91.7% in the 1st quarter. NEXT Financial Group Inc now owns 1,045 shares of the medical research company’s stock valued at $115,000 after acquiring an additional 500 shares during the period. Shine Investment Advisory Services Inc. acquired a new position in Edwards Lifesciences Corporation in the 2nd quarter valued at approximately $126,000. Cornerstone Advisors Inc. increased its position in Edwards Lifesciences Corporation by 25.1% in the 2nd quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock valued at $129,000 after acquiring an additional 219 shares during the period. Alexandria Capital LLC increased its position in Edwards Lifesciences Corporation by 1.7% in the 2nd quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock valued at $136,000 after acquiring an additional 19 shares during the period. Finally, Captrust Financial Advisors acquired a new position in Edwards Lifesciences Corporation in the 2nd quarter valued at approximately $149,000. Hedge funds and other institutional investors own 82.36% of the company’s stock.
Several equities research analysts have recently weighed in on EW shares. Zacks Investment Research upgraded shares of Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $125.00 price objective for the company in a research report on Monday, May 22nd. William Blair reiterated an “outperform” rating on shares of Edwards Lifesciences Corporation in a research report on Monday, August 28th. Barclays PLC increased their price objective on shares of Edwards Lifesciences Corporation from $108.00 to $120.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 27th. Canaccord Genuity reiterated a “buy” rating and set a $150.00 price objective on shares of Edwards Lifesciences Corporation in a research report on Wednesday, June 28th. Finally, Royal Bank Of Canada reiterated a “buy” rating and set a $130.00 price objective on shares of Edwards Lifesciences Corporation in a research report on Friday, September 1st. Six equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $120.75.
In other news, VP Donald E. Bobo, Jr. sold 5,600 shares of the company’s stock in a transaction dated Thursday, June 29th. The shares were sold at an average price of $117.15, for a total transaction of $656,040.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Michael A. Mussallem sold 32,900 shares of the company’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $114.80, for a total transaction of $3,776,920.00. The disclosure for this sale can be found here. Insiders have sold a total of 163,541 shares of company stock worth $18,712,719 in the last 90 days. Company insiders own 2.13% of the company’s stock.
Edwards Lifesciences Corporation (EW) traded up 1.79% during mid-day trading on Friday, reaching $113.50. 1,944,139 shares of the company were exchanged. The stock has a 50-day moving average price of $113.99 and a 200 day moving average price of $108.88. The company has a market capitalization of $23.97 billion, a PE ratio of 34.43 and a beta of 0.64. Edwards Lifesciences Corporation has a one year low of $81.12 and a one year high of $121.75.
Edwards Lifesciences Corporation (NYSE:EW) last posted its earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.88 by $0.20. The business had revenue of $842.00 million for the quarter, compared to analysts’ expectations of $839.16 million. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. The business’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.76 EPS. Analysts predict that Edwards Lifesciences Corporation will post $3.78 EPS for the current year.
Edwards Lifesciences Corporation Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Stock Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related stocks with our FREE daily email newsletter.